ESMO 2019: Abemaciclib Shows Promise in Hormone Receptor- and HER-Positive Advanced Breast Cancer
Randomized monarcHER trial is first of its kind, opens door to further evaluation of CDK4/6 inhibitors in this setting
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.